Year |
Citation |
Score |
2020 |
Bhattacharya D, Pomeroy SL, Pomeranz Krummel DA, Sengupta S. Epigenetics and survivorship in pediatric brain tumor patients. Journal of Neuro-Oncology. PMID 32451770 DOI: 10.1007/S11060-020-03535-3 |
0.6 |
|
2020 |
Pomeranz Krummel DA, Nasti TH, Izar B, Press RH, Xu M, Lowder L, Kallay L, Rupji M, Rosen H, Su J, Curran W, Olson J, Weinberg B, Schniederjan M, Neill S, ... ... Sengupta S, et al. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases. International Journal of Radiation Oncology, Biology, Physics. PMID 32057994 DOI: 10.1016/J.Ijrobp.2020.01.043 |
0.308 |
|
2020 |
Chakraborty S, Dlie ZY, Mukherjee B, Besra SE, Sengupta S, Sen R, Mukherjee A. A Comparative Investigation of the Ability of Various Aptamer-Functionalized Drug Nanocarriers to Induce Selective Apoptosis in Neoplastic Hepatocytes: In Vitro and In Vivo Outcome. Aaps Pharmscitech. 21: 89. PMID 32026264 DOI: 10.1208/S12249-020-1629-Z |
0.327 |
|
2020 |
Bhattacharya D, Krummel DP, Sengupta S. Pediatric cerebellar tumors: transcriptionally distinct but developmentally heterogeneous Translational Cancer Research. 9: 1322-1325. DOI: 10.21037/Tcr.2020.01.31 |
0.363 |
|
2019 |
Cicka D, Ford CL, Templin E, Pitts Z, Gurbani S, Eaton B, Lowder L, Olson J, Weinberg BD, Shim H, Sengupta S. Presentation of treatment effect in glioblastoma after dose-escalation radiation therapy. Oxford Medical Case Reports. 2019: omz085. PMID 31772751 DOI: 10.1093/Omcr/Omz085 |
0.306 |
|
2019 |
Kallay L, Keskin H, Ross A, Rupji M, Moody OA, Wang X, Li G, Ahmed T, Rashid F, Stephen MR, Cottrill KA, Nuckols TA, Xu M, Martinson DE, Tranghese F, ... ... Sengupta S, et al. Modulating native GABA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death. Journal of Neuro-Oncology. PMID 30725256 DOI: 10.1007/S11060-019-03115-0 |
0.401 |
|
2019 |
Kallay L, Keskin H, Ross A, Rupji M, Moody OA, Wang X, Li G, Ahmed T, Rashid F, Stephen MR, Cottrill KA, Nuckois A, Xu M, Martinson DE, Tranghese F, ... ... Sengupta S, et al. Abstract 2623: Modulating native GABAA receptors in medulloblastoma with positive allosteric benzodiazepine-derivatives induces cell death Cancer Research. 79: 2623-2623. DOI: 10.1158/1538-7445.Am2019-2623 |
0.42 |
|
2019 |
Burnhamm A, Kaluzova M, Kallay L, Li G, Ahmed T, Rashid F, Jenkins A, Cook J, Krummel DP, Sengupta S. Abstract 255: Antagonizing Na-K-Cl cotransporter NKCC1 impairs medulloblastoma cell viability Cancer Research. 79: 255-255. DOI: 10.1158/1538-7445.Am2019-255 |
0.397 |
|
2019 |
Kaluzova M, Nasti T, Chen H, Lowder L, Press R, Rosen H, Rupji M, Kallay L, Patel R, Burnham A, Xu M, Ross A, Keskin H, Connelly E, Izar B, ... ... Sengupta S, et al. Abstract 247: Identification of the GABAAreceptor in melanoma brain metastases patient tumors and demonstration that it is a viable drug target using benzodiazepine-derivatives Cancer Research. 79: 247-247. DOI: 10.1158/1538-7445.Am2019-247 |
0.437 |
|
2019 |
Pomeranz Krummel D, Nasti T, Izar B, Xu M, Lowder L, Press R, Kaluzova M, Kallay L, Rupji M, Burnham A, Li G, Ahmed T, Rosen H, Connolly E, Keskin H, ... ... Sengupta S, et al. EXTH-12. RADIATION ENHANCES MELANOMA RESPONSE TO IMMUNOTHERAPY AND SYNERGIZES WITH BENZODIAZEPINES TO PROMOTE ANTI-TUMOR ACTIVITY Neuro-Oncology. 21: vi84-vi84. DOI: 10.1093/Neuonc/Noz175.346 |
0.439 |
|
2018 |
Doyle SP, Gurbani SS, Ross AS, Rosen H, Barrett CD, Olson JJ, Shim H, Shu HK, Sengupta S. The role of erlotinib and the Optune device in a patient with an epidermal growth factor receptor viii amplified glioblastoma. Oxford Medical Case Reports. 2018: omy095. PMID 30410775 DOI: 10.1093/Omcr/Omy095 |
0.339 |
|
2018 |
Clark AR, Calligaris D, Regan MS, Pomeranz Krummel D, Agar JN, Kallay L, MacDonald T, Schniederjan M, Santagata S, Pomeroy SL, Agar NYR, Sengupta S. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. Journal of Neuro-Oncology. PMID 30128689 DOI: 10.1007/S11060-018-2978-2 |
0.591 |
|
2018 |
Melms JC, Ho KW, Thummalapalli R, Tyler J, Brinker TJ, Singh V, Sengupta S, Mier J, Izar B. Implementation of cell-free tumor DNA sequencing from the cerebrospinal fluid to guide treatment in a patient with primary leptomeningeal melanoma: A case report. Molecular and Clinical Oncology. 9: 58-61. PMID 29977540 DOI: 10.3892/Mco.2018.1621 |
0.347 |
|
2018 |
Archer TC, Sengupta S, Pomeroy SL. Brain cancer genomics and epigenomics. Handbook of Clinical Neurology. 148: 785-797. PMID 29478614 DOI: 10.1016/B978-0-444-64076-5.00050-8 |
0.698 |
|
2018 |
Kallay L, Keskin H, Ross A, Moody O, Cottrill K, Nuckols A, Li G, Ahmed T, Rashid F, Stephen M, Xu M, Martinson D, Macdonald T, Kowalski J, Wang X, ... ... Sengupta S, et al. PDTM-45. POSITIVE MODULATION OF NATIVE GABAA RECEPTORS IN MEDULLOBLASTOMA CANCER CELLS WITH BENZODIAZEPINES INDUCES RAPID MITOCHONDRIAL FRAGMENTATION AND TP53-DEPENDENT, CELL CYCLE-INDEPENDENT APOPTOSIS Neuro-Oncology. 20: vi213-vi213. DOI: 10.1093/Neuonc/Noy148.884 |
0.309 |
|
2017 |
Sengupta S, Pomeranz Krummel D, Pomeroy S. The evolution of medulloblastoma therapy to personalized medicine. F1000research. 6: 490. PMID 28713553 DOI: 10.12688/F1000Research.10859.1 |
0.583 |
|
2017 |
Calligaris D, Clark A, Kallay L, Krummel DP, Agar J, Schniederjan M, Pomeroy S, Agar NY, Sengupta S. PATH-04. DISTINGUISHING PINEOBLASTOMA FROM MEDULLOBLASTOMAS USING TISSUE MASS SPECTROMETRY IMAGING Neuro-Oncology. 19: vi171-vi171. DOI: 10.1093/Neuonc/Nox168.695 |
0.473 |
|
2016 |
Jonas O, Calligaris D, Methuku KR, Poe MM, Francois JP, Tranghese F, Changelian A, Sieghart W, Ernst M, Krummel DA, Cook JM, Pomeroy SL, Cima M, Agar NY, Langer R, ... Sengupta S, et al. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. Journal of Biomedical Nanotechnology. 12: 1297-302. PMID 27319222 DOI: 10.1166/Jbn.2016.2262 |
0.587 |
|
2015 |
Ippen FM, Mahadevan A, Wong ET, Uhlmann EJ, Sengupta S, Kasper EM. Stereotactic Radiosurgery for Renal Cancer Brain Metastasis: Prognostic Factors and the Role of Whole-Brain Radiation and Surgical Resection. Journal of Oncology. 2015: 636918. PMID 26681942 DOI: 10.1155/2015/636918 |
0.303 |
|
2014 |
Sengupta S, Weeraratne SD, Cho YJ, Pomeroy SL. Could α5-GABA-A receptor activation be used as a target for managing medulloblastomas? Cns Oncology. 3: 245-7. PMID 25286034 DOI: 10.2217/Cns.14.27 |
0.743 |
|
2014 |
Sengupta S, Weeraratne SD, Sun H, Phallen J, Rallapalli SK, Teider N, Kosaras B, Amani V, Pierre-Francois J, Tang Y, Nguyen B, Yu F, Schubert S, Balansay B, Mathios D, et al. α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathologica. 127: 593-603. PMID 24196163 DOI: 10.1007/S00401-013-1205-7 |
0.727 |
|
2014 |
Jonas O, Sengupta S, Calligaris D, Poe M, Methuku K, Francois JP, Cook J, Agar N, Pomeroy S, Langer R. ET-24 * A NOVEL TROJAN HORSE FOR IN-VIVO SENSITIVITY TESTING OF MEDULLOBLASTOMA THERAPIES Neuro-Oncology. 16: v84-v84. DOI: 10.1093/Neuonc/Nou255.24 |
0.624 |
|
2012 |
Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, Carneiro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennon NJ, McKenna A, Meldrim J, ... ... Sengupta S, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 488: 106-10. PMID 22820256 DOI: 10.1038/Nature11329 |
0.687 |
|
2012 |
Weeraratne SD, Amani V, Teider N, Pierre-Francois J, Winter D, Kye MJ, Sengupta S, Archer T, Remke M, Bai AH, Warren P, Pfister SM, Steen JA, Pomeroy SL, Cho YJ. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathologica. 123: 539-52. PMID 22402744 DOI: 10.1007/S00401-012-0969-5 |
0.679 |
|
2011 |
Pavel H, Ajeawung N, Faure R, Poirier D, Kamnasaran D, Ajeawung N, Joshi H, Kamnasaran D, Poirier D, Ajeawung N, Kamnasaran D, Lun X, Zemp F, Sun B, Stechishin O, ... ... Sengupta S, et al. PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY Neuro-Oncology. 13: iii107-iii120. DOI: 10.1093/Neuonc/Nor158 |
0.707 |
|
Show low-probability matches. |